Key Takeaways
- DataMeds AI partnered with Tollo Health to debut Health Lives Here, a mobile platform designed for individuals using GLP-1 medications.
- The platform’s distribution includes a collaboration with NFL Alumni Health.
- The company established a pharmacy network beginning with North Carolina’s Moose Pharmacy of Concord.
- MEDS shares declined 11% following the announcement.
- Future expansion targets include Long COVID patients and cancer treatment populations in 2026 and beyond.
Shares of DataMeds AI (MEDS) tumbled 11% Monday following the unveiling of its latest health platform. The stock settled at $3.11 during trading.
The Florida-based healthcare technology firm collaborated with Tollo Health to introduce Health Lives Here, a mobile platform designed specifically for individuals taking GLP-1 receptor agonist medications.
Distribution of the platform involves a collaboration with NFL Alumni Health, the wellness division of the National Football League Alumni Association.
New Healthcare Network Debuts With Platform
Accompanying the platform release is the Health Lives Here healthcare network. The network launches with independent pharmacies selected from Corexa Health subsidiary’s established pharmacy roster.
North Carolina’s Moose Pharmacy of Concord serves as the inaugural network participant. Additional pharmacy locations are anticipated to join subsequently.
The platform enables users to access licensed healthcare providers for remote medical consultations. Individuals can receive GLP-1 therapy evaluations directly through their mobile devices.
Through Corexa’s pharmaceutical division, patients can access branded GLP-1 medications via cash payment. Direct-to-home delivery is available, with the alternative option of transferring prescriptions to any preferred local pharmacy.
The platform additionally offers Tollo Health’s Forzet, a medical food formulation. The product aims to address muscle depletion associated with weight reduction therapies and requires no prescription.
Platform Integrates Wearable Technology and Artificial Intelligence
Health Lives Here synchronizes with leading wearable devices. Compatible products include Apple Watch, Samsung Galaxy Watch, WHOOP, and Oura Ring.
Features include an artificial intelligence-powered health coach alongside activity tracking capabilities. An AI-driven chatbot monitors for distress indicators and directs users to emergency resources when necessary.
DataMeds AI has ambitions beyond the GLP-1 user base. The firm intends to incorporate Long COVID patient support by the fourth quarter of 2026.
Cancer patient services represent the subsequent expansion phase. The company has not announced a specific timeline for this development.
Diagnostic laboratory services are also under development. These would leverage the company’s Helomics Corporation acquisition, enabling customers to request direct-to-consumer laboratory testing in permitted jurisdictions.
Long-term objectives include implementing digital twin technology. An expanded provider network is scheduled for 2027.
Gerald Commissiong holds the position of Interim Co-CEO at DataMeds AI. He simultaneously serves as CEO of Tollo Health, the platform’s development partner.
The significant stock decline appears unusual considering the product announcement. Market participants may be evaluating implementation challenges alongside the nascent stage of deployment.
Currently, the Health Lives Here platform operates with a single pharmacy partnership. While the company has outlined an extended development timeline, it has not disclosed user adoption metrics or revenue projections associated with the release.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
